STOCK TITAN

Soligenix Inc - SNGX STOCK NEWS

Welcome to our dedicated news page for Soligenix (Ticker: SNGX), a resource for investors and traders seeking the latest updates and insights on Soligenix.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Soligenix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Soligenix's position in the market.

Rhea-AI Summary
Soligenix announces two-year stability of its thermostabilized filovirus vaccine candidates at 40 degrees Celsius (104 degrees Fahrenheit), eliminating the need for cold chain storage and transport. The platform shows potential for pandemic preparedness and addresses the lack of licensed vaccines for Sudan and Marburg viruses. The next generation combined vaccine platform enables thermostabilization of multiple antigens in a single vial. Ongoing collaborations and grants support the advancement of the program. The antigens and adjuvants used in the vaccines have demonstrated full protection against Zaire ebolavirus, Sudan ebolavirus, and Marburg marburgvirus in non-human primates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Soligenix adjourns Annual Meeting to solicit additional votes and adds new proposal for stockholders to ratify the appointment of Cherry Bekaert LLP as independent registered public accounting firm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Soligenix announces recent accomplishments and financial results for Q2 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.22%
Tags
Rhea-AI Summary
RedChip Companies will air interviews with BioVie, Inc. (Nasdaq:BIVI) and Soligenix, Inc. (Nasdaq:SNGX) on The RedChip Money Report®, a sponsored program on Bloomberg TV, this Saturday, August 12, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
none
-
Rhea-AI Summary
Soligenix opens patient enrollment for a study supported by a $2.6 million FDA grant. The study will evaluate the expanded treatment with HyBryte™ in patients with early-stage CTCL. Positive Phase 3 results and potential for a second confirmatory study. Limited treatment options for CTCL patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.85%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.02%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
Soligenix Inc

Nasdaq:SNGX

SNGX Rankings

SNGX Stock Data

4.06M
10.48M
0.1%
3.66%
1.1%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Princeton

About SNGX

soligenix, inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous t-cell lymphoma, oral mucositis, pediatric crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.